increased mortality in some studies, [11] [12] [13] whereas in other studies, no association between mortality and inappropriate shocks has been found. [14] [15] [16] Whether inappropriate shocks are causally related to increased mortality or indirectly related to mortality by the supraventricular arrhythmias triggering them [16] [17] [18] has been difficult to establish. [11] [12] [13] [14] 19 Increasingly, device therapy programming considerations have emphasized antitachycardia pacing (ATP). 20 Although ATP may reduce shocks and improve quality of life, the effect of ATP on mortality, if any, remains unknown. 21 In the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy 22, 23 (MADIT-RIT) study, we investigated the effect of 2 novel ICD programming strategies on inappropriate therapy. Randomization of patients to high-rate ICD device programming with ICD therapy beginning at 200 beats per minute or to delayed programming (12-60 seconds before ATP or shock) was associated with reductions in inappropriate therapy when compared with conventional programming. Mortality was higher with conventional programming than in the other 2 programming arms. In the current MADIT-RIT substudy, we investigated the factors associated with mortality in the 3 treatment arms of this randomized trial. Based on potentially harmful consequences of inappropriate therapies, we hypothesized that the higher mortality rate seen with conventional programming was because of, in part, the high frequency of inappropriate ICD therapies in this treatment arm when compared with the other 2 treatment arms.
Methods

MADIT-RIT Randomization, Programming, and Interrogation
MADIT-RIT 22, 23 enrolled 1500 patients with guideline-indicated, 24 primary prevention ICD or CRT-D devices at 98 centers in the United States, Canada, Europe, Israel, and Japan from September 15, 2009 , to October 10, 2011. Commercially available dual-chamber ICD or CRT-D Boston Scientific devices were used as appropriate. Dualchamber ICD devices were used to permit the same programming discriminators in patients with CRT-D and ICD devices and to optimize arrhythmia adjudication. Subjects were randomized to 1 of 3 different programming arms. Arm A, conventional programming, used VT detection 170 to 199 beats per minute with a 2.5-second delay before therapy (ATP or shock) and a faster VT and VF zone >200 beats per minute with a 1-second delay before therapy. Arm B, highrate programming, had a monitor-only zone from 170 to 199 beats per minute and a therapy zone at ≥200 beats per minute with a 2.5-second delay before therapy. Arm C, delayed therapy, consisted of 3 therapy zones: zone 1 provided therapy from 170 to 199 beats per minute after a 60-second delay; zone 2, 200 to 249 beats per minute, used a 12-second delay before therapy; and zone 3 treated VT/VF >250 beats per minute after a 2.5-second delay. Atrial discriminators were turned on in all arms. For the conventional and high-rate programming arms, onset and stability detection were used, whereas in the delayed programming arm, Rhythm ID detection algorithms were used. Physician investigators were encouraged to follow optimal pharmacological treatment for the enrolled patients according to current guidelines. 25 The protocol allowed reprogramming of the devices after an inappropriate ICD therapy. Device interrogations were conducted every 3 months the first year and every 6 months thereafter. Postmortem device interrogation was encouraged.
The current data represent version 2 of the MADIT-RIT data, with follow-up conducted until July 10, 2012.
MADIT-RIT was approved by an institutional review committee, and all patients gave informed consent before being enrolled in the study.
End Points
The primary end point of MADIT-RIT was first occurrence of inappropriate therapy; all-cause mortality was a secondary end point. 22, 23 For the current analysis, all-cause mortality was used as the primary end point. An independent morbidity and mortality committee adjudicated and classified deaths as cardiac, noncardiac, or unknown based on an assessment of all the information provided by the enrolling centers, including medical history, description of the circumstances surrounding the death from family members and hospital personnel, physician's determination of the cause of death, death records, and, when available, postmortem ICD interrogation.
ICD Therapy and Arrhythmia Definitions
All ICD therapies from in-clinic and available postmortem interrogations (18 of 71 deaths; 25%) were adjudicated by an independent device interrogation committee. Appropriate ICD therapy was defined as any ICD therapy rendered for VT or VF. Inappropriate ICD therapy was defined as any ICD therapy delivered where VT or VF was not present. 22 Appropriate and inappropriate ICD therapies were subdivided as ATP or shock. If both ATP and shock occurred in an episode, it was considered a shocked episode.
Pharmacotherapy
Cardiovascular pharmacotherapy, including β-blockers, statins, diuretics, digitalis, angiotensin II receptor blocker, angiotensinconverting enzyme inhibitor, aldosterone antagonists, and amiodarone, was recorded at each visit. The influence of pharmacotherapy on all-cause mortality was investigated by incorporating either baseline or in-trial use into multivariate Cox proportional hazard regression models. Time-dependent pharmacotherapy throughout the study period was adjusted for by creating variables for each drug taking into account the time each patient was either on or off the specific drug.
Statistics
Baseline characteristics were compared between patients who died and survivors. Comparisons between groups used χ 2 or Fisher exact tests for categorical variables and Wilcoxon rank-sum test for continuous measures.
The cumulative proportion of all-cause mortality was calculated using the method of Kaplan-Meier. In-trial mortality risk was analyzed in all 1500 patients by multivariate Cox proportional hazards regression models, adjusting for baseline predictors of death found by best subset analysis, setting the limit for inclusion in the model at P<0.05. The selected model was then used to analyze the influence of: ICD therapy throughout the study, pharmacotherapy throughout the study, and randomized programming arm on the end point of all-cause mortality.
We created time-dependent variables for appropriate shock, appropriate ATP only, inappropriate shock, and inappropriate ATP only. The shock and ATP-only groups were defined based on the assumption that appropriate and inappropriate ICD therapies were 2 different entities, and therefore, any potential overlaps between appropriate and inappropriate ICD therapies were not included in the definition. Furthermore, shocks were assumed to be more detrimental than ATP, and therefore, patients in the ATP-only groups were defined as ATP without prior shock. They contributed with risk time in the ATP-only group until they received a shock, and afterward they contributed with risk time in the shock groups.
The proportional hazards assumption was checked in the multivariate models by the use of time-dependent covariates created by interacting survival time with the various covariates and testing for statistical significance using the likelihood ratio test.
Covariate interactions were systematically investigated between programming arms and baseline variables, ICD therapies, and pharmacotherapies. Interactions were also checked between the specific types of ICD therapy (appropriate therapy [ATP only or shock] and inappropriate therapy [ATP only or shock]), baseline variables, and Clinical Perspective on p 792 pharmacotherapy. A significance limit for interactions was set at P<0.01, to account for multiple comparisons. No significant interactions were found.
Hazard ratios with their 95% confidence intervals and 2-sided P values are reported. A 2-tailed P value <0.05 was considered statistically significant.
Analyses were performed using SAS software version 9.3 (SAS Institute, Cary, NC).
Results
During a mean follow-up period of 1.4±0.6 years, 71 of 1500 (5%) enrolled patients died with 34, 16, and 21 deaths in the conventional, high-rate, and delayed programming arms, respectively ( Figure 1 ). The 2.5-year cumulative probability of death was 9%. The adjudicated cause of death was cardiac in 40 patients (56.3%), noncardiac in 23 patients (32.4%), and unknown in 8 patients (11.3%; Figure 1 ). The majority of cardiac deaths were because of heart failure, closely followed by sudden cardiac death ( Figure 1 ). The proportions of cardiac deaths were equally distributed among the programming arms, whereas the percentage of noncardiac deaths was higher in the conventional and delayed programming arms compared with the high-rate programming arm. Most of the noncardiac death in the conventional programming arm was related to cancer (n=8).
Baseline Factors and All-Cause Mortality
Patients who died were significantly older, had lower left ventricular ejection fraction, lower diastolic blood pressure, and were more likely to have ischemic cardiomyopathy, diabetes mellitus, and to receive amiodarone and digitalis at baseline compared with patients who survived (Table 1) .
Similarly, in multivariate analysis, older age, lower diastolic blood pressure, New York Heart Association class III (compared with lower New York Heart Association class), lower left ventricular ejection fraction, ischemic cardiomyopathy, diabetes mellitus, and implantation of an ICD (compared with a CRT-D) were significantly associated with an increased risk of all-cause mortality ( Table 2) .
ICD Therapy and All-Cause Mortality
During follow-up, appropriate ICD therapy occurred in 186 of 1500 patients (12.4%). Inappropriate ICD therapy, largely because of atrial tachyarrhythmia, occurred in 152 of 1500 patients (10.1%). Patients in the conventional programming arm received a higher frequency of both appropriate and inappropriate therapies compared with patients in the other 2 treatment arms. Figure 2 shows the breakdown of patients who died with known antecedent appropriate or inappropriate ICD therapies.
In multivariate analyses, both appropriate and inappropriate therapies were significantly associated with increased risk of all-cause mortality ( Table 3 ). Increased risk of mortality was associated with the delivery of appropriate shock, inappropriate shock, and inappropriate ATP only (Table 3) . No increased risk of mortality was found in the 112 patients who experienced appropriate ATP only ( Table 3 ). The significant associations persisted after adjustment for programming arm and time-dependent pharmacotherapy (results not shown). During the course of the follow-up, a total of 7 inappropriate therapies (in 6 patients) induced VT/VF requiring appropriate device therapy. Three patients experienced such an induced VT/VF event in conventional arm, 3 in high-rate arm, and 1 in the delayed arm. None of these patients died during the trial.
Assessing the risk of mortality associated with ICD therapies by heart rate range revealed that inappropriate ICD therapy in the 170 to 199 beats per minute range was associated with a significantly increased risk of death, whereas appropriate ICD therapy in the same heart rate range had no associated mortality risk ( Table 4 ). The risk of mortality was increased in patients who experienced appropriate ICD therapy ≥200 beats per minute, although we were unable to show an increased risk of mortality with inappropriate ICD therapy ≥200 beats per minute (Table 4) .
Compared with first ICD events, multiple ICD therapies of the same type did not result in an additional increase in mortality risk considering appropriate shocks, inappropriate shocks, inappropriate ATP only, or appropriate ATP only (P=0.30-0.75). However, only limited numbers of deaths were present in patients with multiple ICD therapies (events: appropriate shock=5, inappropriate shock=1, appropriate ATP=1, inappropriate ATP=2). When considering the number of specific ICD therapies within each ICD therapy episode, the number of rendered inappropriate therapies was twice as high as the number of rendered appropriate ICD therapies ( Table 5 ).
Pharmacotherapy and All-Cause Mortality
In multivariate analysis, after adjusting for baseline predictors of death and for ICD therapy, the time-dependent use of amiodarone (hazard ratio, 2.52; 95% confidence interval, 1.34-4.74; P=0.004) and the lack of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use (hazard ratio, 2.59; 95% confidence interval, 1.56-4.31; P<0.001) were associated with increased mortality risk. No other pharmacological treatment was significantly associated with mortality. No differential antiarrhythmic treatment throughout the study was evident between the programming arms. This was confirmed in multivariate analysis where the results were consistent within each programming arm (interaction P=0.12-0.78). Importantly, the influence of ICD therapy on mortality was not altered when adjusting for time-dependent amiodarone and angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use, and the results were similar when further adjustments were made for randomized programming arm (results not shown).
ICD Programming and All-Cause Mortality
Randomization to conventional programming compared with high-rate programming remained significantly associated with increased risk of mortality even after further adjustment for time-dependent ICD therapies and time-dependent use of amiodarone and angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (Table 6 ). A significant mortality risk was not present when comparing conventional programming with delayed programming ( Table 6 ). The results were consistent when considering cardiac mortality ( Table 6 ). During follow-up, 166 patients (11%) deviated from the allocated randomized programming arm on the parameters of rate cut-off, delay before therapy and ATP on/off, with 70 patients randomized to conventional programming, 54 randomized to high-rate programming, and 42 randomized to delayed programming. Of the patients who deviated within the abovementioned parameters, only 9 patients died, with equal distribution among the programming arms (3 events in each arm).
Discussion
In MADIT-RIT, randomization to conventional ICD programming, inappropriate ICD therapy, and appropriate ICD shocks were each independently associated with increased mortality risk after adjustment for relevant risk covariates.
Several mechanisms could potentially explain the association of conventional programming with increased mortality. Inappropriate therapy may have contributed to the differential mortality rates between arms. The sum total of inappropriate and appropriate shocks in the conventional treatment arm was almost twice the number of delivered shock therapies in the high-rate and delayed treatment arms. 23 Thus, the increased frequency of shocks in the conventional treatment arm could contribute additional myocardial injury to an already compromised myocardium with increase in the subsequent risk for heart failure and life-threatening ventricular tachyarrhythmias, as previously suggested. 9 However, inappropriate ATP and shock therapy cannot be the only factor responsible for the increased mortality in the conventional arm. Total deaths numbered 34 in conventional versus 16 in the high-rate and 21 in the delayed therapy arm. However, the number of patients dying after experiencing a confirmed inappropriate therapy was 8 versus 0 versus 2, respectively, and therefore other factors must have contributed to the increased mortality. In multivariate analyses, when adjusted for appropriate and inappropriate therapy, assignment to conventional programming remained an independent predictor of mortality, indicating the presence of an unknown entity in patients programmed to conventional programming that contributed to increased mortality. As seen in Figure 1 , there was a sizable difference in noncardiac deaths between the programming arms, and this was mostly because of cancer-related deaths as adjudicated by the mortality review committee. Although an element of chance might be involved in the higher frequency of cancer-related deaths in the conventional programming arm, it is also possible that cancer patients are especially vulnerable to the increased occurrence of adverse appropriate and inappropriate shocks in the 170 to 199 beats per minute range potentially compromising their limited medical reserve.
Inappropriate ATP only was very frequent in the conventional programming arm, 23 consistent with the increased risk of mortality associated with inappropriate therapy in the 170 to 199 beats per minute range. This association between inappropriate ATP and increased mortality risk was also reported in a recent substudy of the MADIT-CRT trial. 14 However, the mechanism by which inappropriate ATP, by itself, contributed to increased mortality risk is still unclear, because in both the current study and in MADIT-CRT trial, 14 appropriate ATP was not associated directly with any harm. In the current study, inappropriate ATP only was not a marker for risk related to supraventricular tachyarrhythmias, because device interrogations revealed that the cumulative frequency of these arrhythmias in the 170 to 199 beats per minute range was almost identical (21-22%) in the conventional and high-rate treatment arms. 26 Inappropriate ATP can be proarrhythmic, 27 but such episodes of direct and immediate harm were very infrequent, and no fatal ICD proarrhythmic events 10 (from ATP or shock) were documented in MADIT-RIT. As compared with appropriate ATP, when inappropriate ATP was delivered approximately, twice as many pacing sequences resulted. Given that inappropriate therapy is rarely effective in terminating the atrial arrhythmias responsible for triggering the inappropriate response, it is possible that the larger number of sequences may have exerted an adverse influence on the myocardium. However, in summary, based on analysis of the available data, it is not currently possible to determine the mechanism by which inappropriate ATP was significantly associated with increased mortality.
Because MADIT-RIT was designed for analysis as 2 parallel trials, it is intriguing that both high-rate and delayed therapy intervention arms exhibited both a 75% to 80% lower incidence of first inappropriate therapy and also a 44% to 55% mortality reduction. Although the mortality difference was significant only for the conventional versus the high-rate programming arm, the results from the 2 arms are nevertheless mutually supportive. Moreover, the 2-fold higher cardiac mortality in the conventional programming arm compared with the other 2 arms supports the link between ICD therapy and mortality risk. We do, however, acknowledge the risk of confounding by the use of a common comparator group.
Recently, Gasparini et al 28 reported the findings from ADVANCE III (Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients), a randomized trial involving 1902 primary and secondary prevention patients with ICD therapy. They evaluated the use of prolonged (30 of 40) versus standard (18 of 24) VT detection intervals and observed a 38% lower rate of delivered therapies including inappropriate shocks and appropriate ATP and shocks. However, no decreased risk of mortality was found. In MADIT-RIT, the total delivered therapies in the high-rate arm was 66% lower than the delivered therapies in the conventional therapy arm. 23 This difference in delivered therapies between the control and interventional arm of the 2 studies, as well as both the higher detection limit in the control group and the shorter follow-up time in ADVANCE III as compared with MADIT-RIT, may explain the different findings regarding reduction in mortality between the 2 studies. Similar to MADIT-RIT, a trend toward mortality reduction was seen in the shock reduction programming study Primary Prevention Parameters Evaluation. 29 
Study Limitations
Because MADIT-RIT was designed to evaluate the primary end point of first inappropriate therapy, we are limited in power for secondary analysis on the end point of mortality, with relatively Two different Cox models were fitted, one for the end point of all-cause mortality and one for the end point of cardiac mortality. Time-dependent variables represent the risk time in on/off medication/implantable cardioverter defibrillator (ICD) therapy groups throughout the follow-up period. All interaction P values between programming arms and baseline characteristics or ICD therapies had P>0.01. CI indicates confidence interval; and HR, hazard ratio.
*Adjusted for age, left ventricular ejection fraction, diastolic blood pressure, diabetes mellitus, ischemic cardiomyopathy, New York Heart Association (NYHA) class III compared with lower NYHA classes, implanted device (ICD/cardiac resynchronization therapy with defibrillator), time-dependent appropriate and inappropriate ICD therapies, and time-dependent amiodarone usage and lack of angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) usage.
†Adjusted for left ventricular ejection fraction, diastolic blood pressure, ischemic cardiomyopathy, time-dependent appropriate and inappropriate ICD therapies, and time-dependent amiodarone usage and lack of ACEi/ARB usage. few mortality events in each of the programming arms during a comparatively short follow-up period (1.4±0.6 years). This is evident from the P value when comparing conventional programming with high-rate programming (P=0.032). Given the number of statistical tests, the P values reported should be considered as nominal, and it is noted that the difference in all-cause mortality would not reach significance if we had corrected for the 2 comparisons A versus B and A versus C, although it would be very close to significant (significance limit accounting for 2 comparisons: P<0.025, actual P=0.032). Furthermore, by using the conventional programming arm as common comparator, there is a risk of confounding. Second, the ICD device's memory capacity might have led to unavailability of electrograms for some repeat arrhythmia episodes because of overwriting. 22 Third, although adjustments for multiple baseline variables were used to investigate the association of ICD therapy and mortality, there is a possibility that other unmeasured confounders, such as differential medical or surgical management, may have affected the results. Furthermore, postmortem interrogations were only available in 18 of 71 deaths (25%), which make it difficult to assess whether patients had ICD therapy before their death. This limitation might have impacted our results on an unknown level. Lastly, information regarding cancer at baseline was not reported, and cancer at baseline was not an exclusion criterion according to the protocol. Therefore, there is a chance that more patients randomized to conventional programming had cancer at enrollment, as compared with patients randomized to high-rate or delayed programming, which may have contributed to the mortality difference. As previously mentioned, patients with cancer may have less medical reserve because of their chronic illness and thus may be more vulnerable to the increased occurrence of adverse appropriate and inappropriate shocks in the conventional treatment arm.
Conclusions
In MADIT-RIT, appropriate shock, inappropriate shock, and inappropriate ATP were all independent predictors of all-cause mortality, whereas appropriate ATP was not. Conventional ICD programming, beginning therapies at 170 beats per minute, was associated with an increased risk of all-cause mortality as compared with ICD programming with a cutoff >200 beats per minute, even when taking into account ICD therapies delivered. The explanation of the increased mortality seen in MADIT-RIT patients randomized to conventional programming as compared with high-rate programming seems to be multifactorial with contributing risk factors including the higher frequency of inappropriate ATP-only therapies and inappropriate and unnecessary shock therapies in the 170 to 199 beats per minute range. In addition, there could be ≥1 unknown confounding factors as well as a chance effect in the distribution of deaths that may also contribute to a higher mortality in the conventional programming arm.
